Skip to main content

Table 1 Median length of the hazard period and (relative) frequency of the individuals across clinical cohort levels

From: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival

  Lifetime
survival
(n= 287)1
Overall survival
(n= 287)2
Progression-free
survival
(n= 284) 2
Censored (0.12) (0.12) (0.23)
Lifetime 59.2 13.1 6.5
Gender       
   Male 58.8 (0.63) 13.6 (0.63) 6.6 (0.63)
   Female 61.1 (0.37) 12.1 (0.37) 6.4 (0.37)
Race       
   White 59.7 (0.77) 13.1 (0.77) 6.8 (0.77)
   Other 57.7 (0.23) 12.6 (0.23) 5.3 (0.23)
Therapy       
   CRnoT 57.7 (0.40) 15.7 (0.40) 8.0 (0.34)
   R 60.7 (0.35) 12.3 (0.35) 5.3 (0.41)
   CRT 53.4 (0.10) 15.4 (0.10) 6.8 (0.10)
   Other 64.8 (0.08) 14.2 (0.08) 7.9 (0.08)
   None 70.5 (0.07) 2.9 (0.07) 1.4 (0.07)
ProgRec       
   Yes 57.6 (0.77) 15.1 (0.77) - (0.77)
   No 64.8 (0.23) 5.9 (0.23) - (0.23)
  1. 1 expressed in years;
  2. 2 expressed in months.